Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aker ASA
Wellness Industry Executive Decisions: AHPA's McGuffin Notes 20 Years, Aker Promotes McNeil To Innovation VP, More
AHPA's Michael McGuffin notes accomplishments in 20 years he's led trade group; CbdMD signs former NFL players as brand reps; former British Columbia trade official consults with Naturally Splendid; Canadian cannabis firm Emerald Heath appoints CEO, CCO; and Aker Biomarine promotes McNeil to innovation VP.
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.
- Other Names / Subsidiaries
- Aker BioMarine ASA
- Epax Holding AS
- Trygg Pharma AS